Robert Konrad received his M.D. degree from the University of Pennsylvania School of Medicine in Philadelphia, PA and completed a post-doctoral research fellowship and a residency in Laboratory Medicine at the same institution. He is board-certified in Clinical Pathology and is currently a Senior Vice President at Eli Lilly and Company, where he leads the Laboratory for Experimental Medicine. His research interests include cholesterol and triglyceride metabolism as well as apolipoprotein and angiopoietin-like protein (ANGPTL) biology. Dr. Konrad is the author or co-author of more than 130 peer-reviewed scientific papers.